1932
0
  1. Home
  2. A-Z Publications
  3. Annual Review of Public Health
  4. Volume 42, 2021
  5. Article

Annual Review of Public Health

Volume 42, 2021

Prediabetes and What It Means: The Epidemiological Evidence

Abstract

Prediabetes is an intermediate stage between normal glycemia and diabetes and is highly prevalent, especially in older age groups and obese individuals. Five different definitions of prediabetes are used in current practice, which are based on different cut points of HbA, fasting glucose, and 2-h glucose. A major challenge for the field is a lack of guidance on when one definition might be preferred over another. Risks of major complications in persons with prediabetes, including diabetes, cardiovascular disease, kidney disease, and death, also vary depending on the prediabetes definition used. Randomized clinical trials have demonstrated that lifestyle and pharmacologic interventions can be cost-effective, prevent diabetes, and improve cardiovascular risk factors in adults with prediabetes. However, the practical implementation of lifestyle modification or the use of metformin for treating prediabetes is inadequate and complicated by a lack of agreement on how to define the condition. Establishing consensus definitions for prediabetes should be a priority and will help inform expansion of insurance coverage for lifestyle modification and improve current screening and diagnostic practices.

Keyword(s): epidemiology, impaired fasting glucose, impaired glucose tolerance, prediabetes
Loading

Article metrics loading...

/content/journals/10.1146/annurev-publhealth-090419-102644
2021-04-01
2024-04-20
Loading full text...

Full text loading...

/deliver/fulltext/publhealth/42/1/annurev-publhealth-090419-102644.html?itemId=/content/journals/10.1146/annurev-publhealth-090419-102644&mimeType=html&fmt=ahah

Literature Cited

  1. 1. 
    Ackermann RT, O'Brien MJ. 2020. Evidence and challenges for translation and population impact of the Diabetes Prevention Program. Curr. Diab. Rep. 20:39
     [Google Scholar]
  2. 2. 
    ADA (Am. Diabetes Assoc.) 2010. Standards of medical care in diabetes–2010. Diabetes Care 33:Suppl. 1S11–61
     [Google Scholar]
  3. 3. 
    ADA (Am. Diabetes Assoc.) 2020. 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes–2020. Diabetes Care 43:Suppl. 1S14–31
     [Google Scholar]
  4. 4. 
    ADA (Am. Diabetes Assoc.) 2020. 3. Prevention or delay of type 2 diabetes: Standards of Medical Care in Diabetes–2020. Diabetes Care 43:Suppl. 1S32–36
     [Google Scholar]
  5. 5. 
    Alberti KG, Zimmet PZ. 1998. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 15:7539–53
     [Google Scholar]
  6. 6. 
    Ali MK, Bullard KMK, Saydah S, Imperatore G, Gregg EW. 2018. Cardiovascular and renal burdens of prediabetes in the USA: analysis of data from serial cross-sectional surveys, 1988–2014. Lancet Diabetes Endocrinol 6:5392–403
     [Google Scholar]
  7. 7. 
    Ali MK, Echouffo-Tcheugui J, Williamson DF. 2012. How effective were lifestyle interventions in real-world settings that were modeled on the Diabetes Prevention Program?. Health Aff. 31:167–75
     [Google Scholar]
  8. 8. 
    Ali MK, McKeever Bullard K, Imperatore G, Benoit SR, Rolka DB et al. 2019. Reach and use of diabetes prevention services in the United States, 2016–2017. JAMA Netw. Open. 2:5e193160
     [Google Scholar]
  9. 9. 
    Aroda VR, Christophi CA, Edelstein SL, Zhang P, Herman WH et al. 2015. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10-year follow-up. J. Clin. Endocrinol. Metab. 100:41646–53
     [Google Scholar]
  10. 10. 
    Barr ELM, Boyko EJ, Zimmet PZ, Wolfe R, Tonkin AM, Shaw JE. 2009. Continuous relationships between non-diabetic hyperglycaemia and both cardiovascular disease and all-cause mortality: the Australian Diabetes, Obesity, and Lifestyle (AusDiab) study. Diabetologia 52:3415–24
     [Google Scholar]
  11. 11. 
    Barr ELM, Zimmet PZ, Welborn TA, Jolley D, Magliano DJ et al. 2007. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation 116:2151–57
     [Google Scholar]
  12. 12. 
    Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P et al. 2006. Effect of ramipril on the incidence of diabetes. N. Engl. J. Med. 355:1551–52
     [Google Scholar]
  13. 13. 
    Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A et al. 2002. Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51:92796–803
     [Google Scholar]
  14. 14. 
    Bullard KM, Saydah SH, Imperatore G, Cowie CC, Gregg EW et al. 2013. Secular changes in U.S. prediabetes prevalence defined by hemoglobin A1c and fasting plasma glucose: National Health and Nutrition Examination Surveys, 1999–2010. Diabetes Care 36:2286–93
     [Google Scholar]
  15. 15. 
    Burd C, Gruss S, Albright A, Zina A, Schumacher P, Alley D 2020. Translating knowledge into action to prevent type 2 diabetes: Medicare expansion of the National Diabetes Prevention Program lifestyle intervention. Milbank Q 98:1172–19
     [Google Scholar]
  16. 16. 
    Caspersen CJ, Thomas GD, Beckles GLA, Bullard KM. 2015. Secular changes in prediabetes indicators among older-adult Americans, 1999–2010. Am. J. Prev. Med. 48:3253–63
     [Google Scholar]
  17. 17. 
    Chi PW, Cheng TYD, Tsai SP, Hsu HL, Wang SL. 2005. Increased mortality risks of pre-diabetes (impaired fasting glucose) in Taiwan. Diabetes Care 28:112756–61
     [Google Scholar]
  18. 18. 
    Chiasson J-L, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. 2002. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359:93232072–77
     [Google Scholar]
  19. 19. 
    Cowie CC, Casagrande SS, Geiss LS. 2018. Prevalence and incidence of type 2 diabetes and prediabetes. Diabetes in America1–25 Bethesda, MD: Natl. Inst. Diabetes Dig. Kidney Dis 3rd ed.
    [Google Scholar]
  20. 20. 
    Cowie CC, Rust KF, Byrd-Holt DD, Gregg EW, Ford ES et al. 2010. Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988–2006. Diabetes Care 33:3562–68
     [Google Scholar]
  21. 21. 
    Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ et al. 2011. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet 378:978531–40
     [Google Scholar]
  22. 21a. 
    DECODE Study Group 1999. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE Study Group. European Diabetes Epidemiology Group. Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe Lancet 354:9179617–21
     [Google Scholar]
  23. 22. 
    DeFronzo RA. 2009. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58:4773–95
     [Google Scholar]
  24. 23. 
    DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA et al. 2011. Pioglitazone for diabetes prevention in impaired glucose tolerance. N. Engl. J. Med. 364:121104–15
     [Google Scholar]
  25. 24. 
    Diabetes Prev. Progr. Res. Group 2002. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care 25:2165–72
     [Google Scholar]
  26. 25. 
    Diabetes Prev. Progr. Res. Group 2003. Effects of withdrawal from metformin on the development of diabetes in the Diabetes Prevention Program. Diabetes Care 26:4977–80
     [Google Scholar]
  27. 26. 
    Diabetes Prev. Progr. Res. Group 2005. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 54:41150–56
     [Google Scholar]
  28. 27. 
    Diabetes Prev. Progr. Res. Group 2012. The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. Diabetes Care 35:4723–30
     [Google Scholar]
  29. 28. 
    Diabetes Prev. Progr. Res. Group 2015. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol 3:11866–75
     [Google Scholar]
  30. 29. 
    Diabetes Prev. Progr. Res. Group 2019. Long-term effects of metformin on diabetes prevention: identification of subgroups that benefited most in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. Diabetes Care 42:4601–8
     [Google Scholar]
  31. 30. 
    DREAM Trial Invest Gerstein HC, Yusuf S, Bosch J, Pogue J et al. 2006. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368:95411096–105
     [Google Scholar]
  32. 31. 
    Echouffo-Tcheugui JB, Ali MK, Griffin SJ, Narayan KMV. 2011. Screening for type 2 diabetes and dysglycemia. Epidemiol. Rev. 33:163–87
     [Google Scholar]
  33. 32. 
    Eddy DM, Schlessinger L, Kahn R. 2005. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann. Intern. Med. 143:4251–64
     [Google Scholar]
  34. 33. 
    Expert Comm. Diagnosis Classif. Diabetes Mellitus 1997. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:71183–97
     [Google Scholar]
  35. 34. 
    Færch K, Johansen NB, Witte DR, Lauritzen T, Jørgensen ME, Vistisen D. 2015. Relationship between insulin resistance and β-cell dysfunction in subphenotypes of prediabetes and type 2 diabetes. J. Clin. Endocrinol. Metab. 100:2707–16
     [Google Scholar]
  36. 35. 
    Fajans SS. 1973. I. Identification of chemical diabetes. The definition of chemical diabetes. Metabolism 22:2211–17
     [Google Scholar]
  37. 36. 
    Forouhi NG, Luan J, Hennings S, Wareham NJ. 2007. Incidence of type 2 diabetes in England and its association with baseline impaired fasting glucose: the Ely study 1990–2000. Diabet. Med. 24:2200–7
     [Google Scholar]
  38. 37. 
    Galaviz KI, Weber MB, Straus A, Haw JS, Narayan KMV, Ali MK. 2018. Global diabetes prevention interventions: a systematic review and network meta-analysis of the real-world impact on incidence, weight, and glucose. Diabetes Care 41:71526–34
     [Google Scholar]
  39. 38. 
    Genuth S, Alberti KGMM, Bennett P, Buse J, Defronzo R et al. 2003. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26:113160–67
     [Google Scholar]
  40. 39. 
    Gerstein HC, Santaguida P, Raina P, Morrison KM, Balion C et al. 2007. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res. Clin. Pract. 78:3305–12
     [Google Scholar]
  41. 40. 
    Goldberg RB, Aroda VR, Bluemke DA, Barrett-Connor E, Budoff M et al. 2017. Effect of long-term metformin and lifestyle in the Diabetes Prevention Program and its outcome study on coronary artery calcium. Circulation 136:152–64
     [Google Scholar]
  42. 41. 
    Gong Q, Gregg EW, Wang J, An Y, Zhang P et al. 2011. Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia 54:2300–7
     [Google Scholar]
  43. 42. 
    Gong Q, Zhang P, Wang J, Ma J, An Y et al. 2019. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study. Lancet Diabetes Endocrinol 7:6452–61
     [Google Scholar]
  44. 43. 
    Hamman RF, Wing RR, Edelstein SL, Lachin JM, Bray GA et al. 2006. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 29:92102–7
     [Google Scholar]
  45. 44. 
    Haw JS, Galaviz KI, Straus AN, Kowalski AJ, Magee MJ et al. 2017. Long-term sustainability of diabetes prevention approaches: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern. Med. 177:121808–17
     [Google Scholar]
  46. 45. 
    Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S et al. 2005. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann. Intern. Med. 142:5323–32
     [Google Scholar]
  47. 46. 
    Herron CA. 1979. Screening in diabetes mellitus: report of the Atlanta workshop. Diabetes Care 2:4357–62
     [Google Scholar]
  48. 47. 
    Holman RR, Haffner SM, McMurray JJ, Bethel MA, Holzhauer B et al. 2010. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N. Engl. J. Med. 362:161463–76
     [Google Scholar]
  49. 48. 
    Hsu WC, Araneta MRG, Kanaya AM, Chiang JL, Fujimoto W. 2015. BMI cut points to identify at-risk Asian Americans for type 2 diabetes screening. Diabetes Care 38:1150–58
     [Google Scholar]
  50. 49. 
    Huang Y, Cai X, Mai W, Li M, Hu Y. 2016. Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis. BMJ 355:i5953
     [Google Scholar]
  51. 50. 
    James C, Bullard KM, Rolka DB, Geiss LS, Williams DE et al. 2011. Implications of alternative definitions of prediabetes for prevalence in U.S. adults. Diabetes Care 34:2387–91
     [Google Scholar]
  52. 51. 
    Juraschek SP, Steffes MW, Selvin E. 2012. Associations of alternative markers of glycemia with hemoglobin A(1c) and fasting glucose. Clin. Chem. 58:121648–55
     [Google Scholar]
  53. 52. 
    Karve A, Hayward RA. 2010. Prevalence, diagnosis, and treatment of impaired fasting glucose and impaired glucose tolerance in nondiabetic U.S. adults. Diabetes Care 33:112355–59
     [Google Scholar]
  54. 53. 
    Katon JG, Reiber GE, Nelson KM. 2013. Peripheral neuropathy defined by monofilament insensitivity and diabetes status: NHANES 1999–2004. Diabetes Care 36:61604–6
     [Google Scholar]
  55. 54. 
    Kawamori R, Tajima N, Iwamoto Y, Kashiwagi A, Shimamoto K, Kaku K. 2009. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 373:96751607–14
     [Google Scholar]
  56. 55. 
    Kengne AP, Erasmus RT, Levitt NS, Matsha TE. 2017. Alternative indices of glucose homeostasis as biochemical diagnostic tests for abnormal glucose tolerance in an African setting. Prim. Care Diabetes 11:2119–31
     [Google Scholar]
  57. 56. 
    Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM et al. 2002. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346:6393–403
     [Google Scholar]
  58. 57. 
    Knowler WC, Edelstein SL, Goldberg RB, Ackermann RT, Crandall JP et al. 2015. HbA1C as a predictor of diabetes and as an outcome in the Diabetes Prevention Program: a randomized clinical trial. Diabetes Care 38:151–58
     [Google Scholar]
  59. 58. 
    Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ et al. 2009. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 374:97021677–86
     [Google Scholar]
  60. 59. 
    Deleted in proof
  61. 60. 
    Lenters-Westra E, Slingerland RJ. 2014. Three of 7 hemoglobin A1c point-of-care instruments do not meet generally accepted analytical performance criteria. Clin. Chem. 60:81062–72
     [Google Scholar]
  62. 61. 
    Le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW et al. 2017. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet 389:100771399–409
     [Google Scholar]
  63. 62. 
    Li G, Zhang P, Wang J, An Y, Gong Q et al. 2014. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol. 2:6474–80
     [Google Scholar]
  64. 63. 
    Li G, Zhang P, Wang J, Gregg EW, Yang W et al. 2008. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 371:96261783–89
     [Google Scholar]
  65. 64. 
    Lindström J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG et al. 2006. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 368:95481673–79
     [Google Scholar]
  66. 65. 
    Liu C, Foti K, Grams ME, Shin J-I, Selvin E. 2020. Trends in self-reported prediabetes and metformin use in the USA: NHANES 2005–2014. J. Gen. Intern. Med. 35:195–101
     [Google Scholar]
  67. 66. 
    Lorenzo C, Wagenknecht LE, Hanley AJG, Rewers MJ, Karter AJ, Haffner SM. 2010. A1C between 5.7 and 6.4% as a marker for identifying pre-diabetes, insulin sensitivity and secretion, and cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study (IRAS). Diabetes Care 33:92104–9
     [Google Scholar]
  68. 67. 
    Mann DM, Carson AP, Shimbo D, Fonseca V, Fox CS, Muntner P. 2010. Impact of A1C screening criterion on the diagnosis of pre-diabetes among U.S. adults. Diabetes Care 33:102190–95
     [Google Scholar]
  69. 68. 
    Menke A, Casagrande S, Cowie CC. 2016. Prevalence of diabetes in adolescents aged 12 to 19 years in the United States, 2005–2014. JAMA 316:3344–45
     [Google Scholar]
  70. 69. 
    Menke A, Casagrande S, Geiss L, Cowie CC. 2015. Prevalence of and trends in diabetes among adults in the United States, 1988–2012. JAMA 314:101021–29
     [Google Scholar]
  71. 70. 
    Menke A, Rust KF, Cowie CC. 2018. Diabetes based on 2-h plasma glucose among those classified as having prediabetes based on fasting plasma glucose or A1c. Diabetes Vasc. Dis. Res. 15:146–54
     [Google Scholar]
  72. 71. 
    Miller RG, Orchard TJ. 2020. Understanding metabolic memory: a tale of two studies. Diabetes 69:3291–99
     [Google Scholar]
  73. 72. 
    Moin T, Li J, Duru OK, Ettner S, Turk N et al. 2015. Metformin prescription for insured adults with prediabetes from 2010 to 2012: a retrospective cohort study. Ann. Intern. Med. 162:8542–48
     [Google Scholar]
  74. 73. 
    Mudaliar U, Zabetian A, Goodman M, Echouffo-Tcheugui JB, Albright AL et al. 2016. Cardiometabolic risk factor changes observed in Diabetes Prevention Programs in US settings: a systematic review and meta-analysis. PLOS Med 13:7e1002095
     [Google Scholar]
  75. 74. 
    Nakagami T. 2004. Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia 47:3385–94
     [Google Scholar]
  76. 75. 
    Nathan DM, Balkau B, Bonora E, Borch-Johnsen K, Buse JB et al. 2009. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 32:71327–34
     [Google Scholar]
  77. 76. 
    Nathan DM, Barrett-Connor E, Crandall JP, Edelstein SL, Goldberg RB et al. 2015. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the DPP Outcomes Study. Lancet Diabetes Endocrinol 3:11866–75
     [Google Scholar]
  78. 77. 
    Nathan DM, Chew E, Christophi CA, Davis MD, Fowler S et al. 2007. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet. Med. 24:2137–44
     [Google Scholar]
  79. 78. 
    Natl. Diabetes Data Group 1979. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28:121039–57
     [Google Scholar]
  80. 79. 
    NCD Risk Factor Collab. (NCD-RisC) 2015. Effects of diabetes definition on global surveillance of diabetes prevalence and diagnosis: a pooled analysis of 96 population-based studies with 331,288 participants. Lancet Diabetes Endocrinol. 3:8624–37
     [Google Scholar]
  81. 80. 
    Orchard TJ, Temprosa M, Barrett-Connor E, Fowler SE, Goldberg RB et al. 2013. Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study. Diabet. Med. 30:146–55
     [Google Scholar]
  82. 81. 
    Pan X-R, Li G-W, Hu Y-H, Wang J-X, Yang W-Y et al. 1997. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care 20:4537–44
     [Google Scholar]
  83. 82. 
    Parrinello CM, Selvin E. 2014. Beyond HbA1C and glucose: the role of nontraditional glycemic markers in diabetes diagnosis, prognosis, and management. Curr. Diab. Rep. 14:11548
     [Google Scholar]
  84. 83. 
    Parrinello CM, Sharrett AR, Maruthur NM, Bergenstal RM, Grams ME et al. 2016. Racial differences in and prognostic value of biomarkers of hyperglycemia. Diabetes Care 39:4589–95
     [Google Scholar]
  85. 84. 
    Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A et al. 2015. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N. Engl. J. Med. 373:111–22
     [Google Scholar]
  86. 85. 
    Plantinga LC, Crews DC, Coresh J, Miller ER 3rd, Saran R et al. 2010. Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. Clin. J. Am. Soc. Nephrol. 5:4673–82
     [Google Scholar]
  87. 86. 
    Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V. 2006. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 49:2289–97
     [Google Scholar]
  88. 87. 
    Ramachandran A, Snehalatha C, Mary S, Selvam S, Kumar CKS et al. 2009. Pioglitazone does not enhance the effectiveness of lifestyle modification in preventing conversion of impaired glucose tolerance to diabetes in Asian Indians: results of the Indian Diabetes Prevention Programme-2 (IDPP-2). Diabetologia 52:61019–26
     [Google Scholar]
  89. 88. 
    Ratner RE, Christophi CA, Metzger BE, Dabelea D, Bennett PH et al. 2008. Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. J. Clin. Endocrinol. Metab. 93:124774–79
     [Google Scholar]
  90. 89. 
    Rhee MK, Herrick K, Ziemer DC, Vaccarino V, Weintraub WS et al. 2010. Many Americans have pre-diabetes and should be considered for metformin therapy. Diabetes Care 33:149–54
     [Google Scholar]
  91. 90. 
    Richter B, Hemmingsen B, Metzendorf MI, Takwoingi Y. 2018. Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia. Cochrane Database Syst. Rev. 10:10CD012661
     [Google Scholar]
  92. 91. 
    Sacks DB. 2011. A1C versus glucose testing: a comparison. Diabetes Care 34:2518–23
     [Google Scholar]
  93. 92. 
    Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S et al. 2019. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res. Clin. Pract. 157:107843
     [Google Scholar]
  94. 93. 
    Saito T, Watanabe M, Nishida J, Izumi T, Omura M et al. 2011. Lifestyle modification and prevention of type 2 diabetes in overweight Japanese with impaired fasting glucose levels: a randomized controlled trial. Arch. Intern. Med. 171:151352–60
     [Google Scholar]
  95. 94. 
    Saydah SH, Loria CM, Eberhardt MS, Brancati FL. 2001. Subclinical states of glucose intolerance and risk of death in the U.S. Diabetes Care 24:3447–53
     [Google Scholar]
  96. 95. 
    Schneider ALC, Kalyani RR, Golden S, Stearns SC, Wruck L et al. 2016. Diabetes and prediabetes and risk of hospitalization: the Atherosclerosis Risk in Communities (ARIC) study. Diabetes Care 39:5772–79
     [Google Scholar]
  97. 96. 
    Selvin E, Crainiceanu CM, Brancati FL, Coresh J. 2007. Short-term variability in measures of glycemia and implications for the classification of diabetes. Arch. Intern. Med. 167:141545–51
     [Google Scholar]
  98. 97. 
    Selvin E, Parrinello CM, Sacks DB, Coresh J. 2014. Trends in prevalence and control of diabetes in the United States, 1988–1994 and 1999–2010. Ann. Intern. Med. 160:8517
     [Google Scholar]
  99. 98. 
    Selvin E, Rawlings AM, Grams M, Klein R, Sharrett AR et al. 2014. Fructosamine and glycated albumin for risk stratification and prediction of incident diabetes and microvascular complications: a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study. Lancet Diabetes Endocrinol. 2:4279–88
     [Google Scholar]
  100. 99. 
    Selvin E, Rawlings AM, Lutsey PL, Maruthur N, Pankow JS et al. 2015. Fructosamine and glycated albumin and the risk of cardiovascular outcomes and death. Circulation 132:4269–77
     [Google Scholar]
  101. 100. 
    Selvin E, Warren B, He X, Sacks DB, Saenger AK. 2018. Establishment of community-based reference intervals for fructosamine, glycated albumin, and 1,5-anhydroglucitol. Clin. Chem. 64:5843–50
     [Google Scholar]
  102. 101. 
    Shen J, Kondal D, Rubinstein A, Irazola V, Gutierrez L et al. 2016. A multiethnic study of pre-diabetes and diabetes in LMIC. Glob. Heart. 11:161–70
     [Google Scholar]
  103. 102. 
    Siu AL. 2015. Screening for abnormal blood glucose and type 2 diabetes mellitus: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 163:11861–68
     [Google Scholar]
  104. 103. 
    Sorkin JD, Muller DC, Fleg JL, Andres R 2005. The relation of fasting and 2-h postchallenge plasma glucose concentrations to mortality: data from the Baltimore Longitudinal Study of Aging with a critical review of the literature. Diabetes Care 28:112626–32
     [Google Scholar]
  105. 104. 
    Thankappan KR, Sathish T, Tapp RJ, Shaw JE, Lotfaliany M et al. 2018. A peer-support lifestyle intervention for preventing type 2 diabetes in India: a cluster-randomized controlled trial of the Kerala Diabetes Prevention Program. PLOS Med 15:6e1002575
     [Google Scholar]
  106. 105. 
    Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. 2004. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27:1155–61
     [Google Scholar]
  107. 106. 
    Tripathy D, Schwenke DC, Banerji MA, Bray GA, Buchanan TA et al. 2016. Diabetes incidence and glucose tolerance after termination of pioglitazone therapy: results from ACT NOW. J. Clin. Endocrinol. Metab. 101:52056–62
     [Google Scholar]
  108. 107. 
    Tseng E, Greer RC, O'Rourke P, Yeh H-C, McGuire MM et al. 2019. National survey of primary care physicians’ knowledge, practices, and perceptions of prediabetes. J. Gen. Intern. Med. 34:112475–81
     [Google Scholar]
  109. 108. 
    Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H et al. 2001. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 344:181343–50
     [Google Scholar]
  110. 109. 
    Wang L, Gao P, Zhang M, Huang Z, Zhang D et al. 2017. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013. JAMA 317:242515–23
     [Google Scholar]
  111. 110. 
    Warren B, Pankow JS, Matsushita K, Punjabi NM, Daya NR et al. 2017. Comparative prognostic performance of definitions of prediabetes: a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study. Lancet Diabetes Endocrinol 5:134–42
     [Google Scholar]
  112. 111. 
    Weber MB, Ranjani H, Staimez LR, Anjana RM, Ali MK et al. 2016. The stepwise approach to diabetes prevention: results from the D-CLIP randomized controlled trial. Diabetes Care 39:101760–67
     [Google Scholar]
  113. 112. 
    WHO (World Health Organ.) 2006. Definition and diagnosis of diabetes mellitus and intermediate Rep., WHO Geneva: https://www.who.int/diabetes/publications/Definition%20and%20diagnosis%20of%20diabetes_new.pdf
  114. 113. 
    WHO (World Health Organ.) Expert Comm. Diabetes Mellitus 1980. WHO Expert Committee on Diabetes Mellitus Tech. Rep. 646, WHO, Geneva. https://apps.who.int/iris/bitstream/handle/10665/41399/WHO_TRS_646.pdf?sequence=1&isAllowed=y
  115. 114. 
    Xu Y, Wang L, He J, Bi Y, Li M et al. 2013. Prevalence and control of diabetes in Chinese adults. JAMA 310:9948–59
     [Google Scholar]
  116. 115. 
    Zhang X, Gregg EW, Williamson DF, Barker LE, Thomas W et al. 2010. A1C level and future risk of diabetes: a systematic review. Diabetes Care 33:71665–73
     [Google Scholar]
/content/journals/10.1146/annurev-publhealth-090419-102644
Loading
Prediabetes and What It Means: The Epidemiological Evidence
Annual Review of Public Health 42, 59 (2021); https://doi.org/10.1146/annurev-publhealth-090419-102644
/content/journals/10.1146/annurev-publhealth-090419-102644
/content/journals/10.1146/annurev-publhealth-090419-102644
Loading

Data & Media loading...

  • Article Type: Review Article

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error